Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

NCT00637377 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1240

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Ranibizumab
BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

Sponsor

Bayer

Collaborators

[object Object]